BridgeMD
Immune responses in health care personnel
EU CTIS ID: 2024-515372-12-00
What this study is testing
To assess the presence and titer of antibodies against circulating influenza virus strains and vaccine strains of the current season from pre- and post-vaccination serum samples.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female individuals aged 18 to 64 years
- Members of health care or laboratory personnel in HUS having decided to take the seasonal influenza vaccination by the routine occupational health care service
- General good health as established by or volunteer’s own statement
- Written informed consent
- Presumably able and willing to participate in the study during the starting influenza season
You likely can't join if
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- Administration (longer than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months before the vaccination; oral corticosteroids in dosages of 20 mg/day or more prednisolone or equivalent are excluded; inhaled or topical steroids are allowed.
- Pregnancy or lactation
- Acute disease at the time of enrolment (defined as the presence of a moderate or severe illness with or without fever)
- Contraindication for influenza vaccination
- Any other criteria which, in the investigator’s or dedicated study staff member’s opinion, would compromise the ability of a subject to participate in the study, a subject’s well-being, or the outcome of the study
See the full eligibility criteria
- Male or female individuals aged 18 to 64 years
- Members of health care or laboratory personnel in HUS having decided to take the seasonal influenza vaccination by the routine occupational health care service
- General good health as established by or volunteer’s own statement
- Written informed consent
- Presumably able and willing to participate in the study during the starting influenza season
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- Administration (longer than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months before the vaccination; oral corticosteroids in dosages of 20 mg/day or more prednisolone or equivalent are excluded; inhaled or topical steroids are allowed.
- Pregnancy or lactation
- Acute disease at the time of enrolment (defined as the presence of a moderate or severe illness with or without fever)
- Contraindication for influenza vaccination
- Any other criteria which, in the investigator’s or dedicated study staff member’s opinion, would compromise the ability of a subject to participate in the study, a subject’s well-being, or the outcome of the study
- Exclusion criteria for participation in the subgroup giving together 3 times 60 ml blood for analyses of cellular immunity: weight less than 50 kg or diagnosed or suspected anaemia
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.